[Mucosal injury of aclacinomycin A in patients with adult acute leukemia--comparison of BH-AC. AMP therapy and BH-AC. DMP therapy].
Takeyama
H
H
Kataoka
T
T
Yano
K
K
Fukutani
H
H
Watanabe
E
E
D015250:Aclarubicin; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008875:Middle Aged; D009092:Mucous Membrane / Q000187:drug effects; D009279:Naphthacenes / Q000008:administration & dosage / Q000009:adverse effects; D011239:Prednisolone / Q000008:administration & dosage; D001745:Urinary Bladder Diseases / Q000139:chemically induced
D009279:Naphthacenes; D003561:Cytarabine; D015250:Aclarubicin; D011239:Prednisolone; D015122:Mercaptopurine; D003630:Daunorubicin